🧬Tidera Health
⚕️

Educational tool only. Does not confirm eligibility or provide medical advice. Always consult your physician before pursuing any trial.

OncologyICD-10: C53

Find Recruiting Clinical Trials for Cervical Cancer

Search cervical cancer immunotherapy, chemoradiation, and recurrent disease trials — matched to your stage and PD-L1 status.

🔍 Search Cervical Cancer Trials →

About Cervical Cancer

Cervical cancer is the 4th most common cancer in women globally, predominantly caused by persistent HPV infection (HPV 16 and 18 account for ~70% of cases). While vaccination and screening programs have reduced incidence in high-income countries, cervical cancer remains a leading cause of cancer mortality in low- and middle-income countries. Treatment for early-stage disease (surgery, chemoradiation) is often curative, but metastatic or recurrent cervical cancer carries a poor prognosis. The addition of pembrolizumab (anti-PD-1) to standard chemotherapy + bevacizumab has improved outcomes in PD-L1-positive metastatic disease.

What Types of Cervical Cancer Clinical Trials Exist?

Cervical cancer trials are active in locally advanced, metastatic, and recurrent settings. Immunotherapy combination trials test checkpoint inhibitor + chemoradiation (for locally advanced disease), checkpoint inhibitor + bevacizumab combinations, and novel ADCs (tisotumab vedotin). HPV-targeted cellular immunotherapy trials (therapeutic vaccines, T-cell receptor engineered therapies targeting HPV E6/E7 antigens) represent a novel area. PD-L1 CPS (combined positive score) ≥1 is the biomarker for pembrolizumab eligibility. FIGO stage, prior treatment, and HPV status are standard eligibility variables.

Find Recruiting Cervical Cancer Trials Near You

Enter your profile and we'll search ClinicalTrials.gov in real time — matching trials to your age, location, and treatment history. Free, no account required.

Search Cervical Cancer Trials →

Data from ClinicalTrials.gov · Updated in real time · Educational use only

Frequently Asked Questions

What clinical trials are available for cervical cancer?▾
Recruiting cervical cancer trials include checkpoint inhibitor combinations for locally advanced disease (concurrent with chemoradiation), pembrolizumab combination extension studies for metastatic disease, ADC trials (tisotumab vedotin combinations), therapeutic HPV vaccine trials (T-cell receptor therapies targeting E6/E7 antigens), and clinical trials in recurrent/refractory disease.
Does PD-L1 status matter for cervical cancer trials?▾
Yes. Pembrolizumab is FDA-approved for PD-L1 CPS ≥1 metastatic cervical cancer (in combination with chemotherapy + bevacizumab). Many immunotherapy trials require PD-L1 CPS ≥1 or ≥10. PD-L1 testing is performed on tumor tissue using the 22C3 pharmacDx assay. Patients with PD-L1 CPS <1 have fewer immunotherapy options but remain eligible for ADC and other trials.
Are there cervical cancer trials for earlier stages?▾
Yes. Locally advanced cervical cancer (Stage IB3–IVA) trials test checkpoint inhibitor addition to concurrent chemoradiation (cisplatin + radiation). Adjuvant trials test post-chemoradiation consolidation therapy. High-risk early-stage disease (lymph node involvement after surgery) trials test adjuvant checkpoint inhibitors or chemotherapy intensification.

Related Conditions

Ovarian CancerBreast CancerMelanoma

Data source: All clinical trial information is sourced from ClinicalTrials.gov, the official U.S. registry maintained by the National Library of Medicine. Tidera Health is an independent educational platform and is not affiliated with ClinicalTrials.gov or the National Library of Medicine. Always verify trial details directly with the research coordinator or your physician.